https://www.selleckchem.com/products/pf429242.html
Good partial responses (Miller Payne grades 3,4) were observed in 32.5% of patients. The remaining 6.5% were poor responders. Seventy-seven patients underwent surgery. The disease-free survival at 1 and 3 years for those who had a pathological complete response was 96.7% and 77.6%, respectively, and 92.3% and 62.7% for those who did not, respectively. The predominant adverse events were hematological, with anemia being the most common one. The addition of cisplatin to neoadjuvant chemotherapy with anthracycline and taxane in TNBC was t
إعجاب
علق
شارك
